ホーム › びまん性大細胞型B細胞リンパ腫 › バージニア
バージニアにおけるびまん性大細胞型B細胞リンパ腫の臨床試験
バージニア内の拠点で、びまん性大細胞型B細胞リンパ腫に関する17件の研究が参加者を募集しています。
バージニア内の都市
公式研究テキスト（英語）
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
- University of Virginia Cancer Center, Charlottesville
- VCU Massey Comprehensive Cancer Center, Richmond
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/01更新 · NCT06649812A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Virginia Commonwealth University Massey Cancer Center, Richmond
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/28更新 · NCT05006716A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
- Virginia Cancer Specialists, PC ( Site 8003), Manassas
- VCU Health Adult Outpatient Pavillion ( Site 0138), Richmond
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06890884A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- University of Virginia Cancer Center ( Site 0138), Charlottesville
- Virginia Cancer Institute ( Site 0148), Richmond
- Blue Ridge Cancer Care ( Site 0132), Roanoke
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06717347Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
- Virginia Cancer Specialists, PC, Fairfax
- Virginia Oncology Associates - Virginia Beach, Virginia Beach
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/11更新 · NCT06806033Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
- University of Virginia, Charlottesville
- Virginia Cancer Specialists, Fairfax
- Virginia Oncology Associates - Norfolk, Norfolk
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/31更新 · NCT06500273A Study of ARC-02 in B-cell NHL
- Massey Cancer Center, Richmond
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/26更新 · NCT07691606Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Virginia Oncology Associates, Norfolk
- Virginia Commonwealth University-Massey Cancer Center, Richmond
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/25更新 · NCT05826535Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
- VCU Massey Comprehensive Cancer Center, Richmond
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/25更新 · NCT06536049A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
- University of Virginia Health System, Charlottesville
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/19更新 · NCT04104776A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Virginia Oncology Associates, Norfolk
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/04更新 · NCT07188558Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma
- University of Virginia Health System, Charlottesville
被験者募集中第2相
18歳以上 · 全性別 · 2026/07/10更新 · NCT05852717Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- University of Virginia Cancer Center, Charlottesville
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/09更新 · NCT06015880Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- VCU Massey Comprehensive Cancer Center, Richmond
被験者募集中第2相
18歳以上 · 全性別 · 2026/02/02更新 · NCT05633615Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+
- Virginia Commonwealth University, Richmond
被験者募集中第2相
18歳以上 · 全性別 · 2026/01/23更新 · NCT06846463Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
- VCU Massey Cancer Center at Stony Point, Richmond
- VCU Massey Comprehensive Cancer Center, Richmond
被験者募集中第2相
18歳以上 · 全性別 · 2025/10/20更新 · NCT05890352A Study of NX-1607 in Adults With Advanced Malignancies
- University of Virginia, Charlottesville
被験者募集中第1相
18歳以上 · 全性別 · 2025/09/09更新 · NCT05107674ClinicalTrials.govより、2026/10/02時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。